Recent developments in the treatment of adult atopic dermatitis.
Atopic dermatitis is a common inflammatory skin condition with increasing incidence in recent decades. The mainstay of treatment has been the combination of emollients and topical corticosteroids, with the addition of systemic therapies in severe cases. New drugs such as the topical calcineurin inhibitors have shown promise in treating mild-to-severe atopic dermatitis. Other novel therapies that have been reported in the literature include leukotriene antagonists, monoclonal antibodies such as infliximab, leflunomide, recombinant interferon gamma and intravenous immunoglobulin. This review will focus on the treatment of adult atopic dermatitis.
Pua
Vernon S C
VS
Department of Dermatology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Barnetson
Ross StC
RS
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007371:Interferon-gamma / Q000627:therapeutic use; D007555:Isoxazoles / Q000627:therapeutic use; D007641:Keratolytic Agents / Q000627:therapeutic use*; D000077339:Leflunomide; D020024:Leukotriene Antagonists / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D065095:Calcineurin Inhibitors; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D007641:Keratolytic Agents; D020024:Leukotriene Antagonists; D007371:Interferon-gamma; D000077339:Leflunomide